Literature DB >> 12478138

Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review.

Richard M Hoffman1, Roderick MacDonald, Joel W Slaton, Timothy J Wilt.   

Abstract

PURPOSE: We conducted a systematic review of randomized controlled trials evaluating the efficacy and safety of laser prostatectomy techniques compared to transurethral resection of the prostate for symptomatic benign prostatic obstruction.
MATERIALS AND METHODS: We searched MEDLINE, the Cochrane library and reference lists of retrieved studies to identify randomized trials of 6 months or greater in duration with at least 10 subjects in each treatment arm. We extracted data on study design, subject and treatment characteristics, adverse events, urinary symptoms and urinary flow.
RESULTS: A total of 16 studies involving 1,488 subjects were evaluated, including 8 comparisons of transurethral resection with contact lasers, 7 with noncontact lasers and 4 with hybrid techniques. Study duration ranged from 6 to 36 months. Mean patient age (67.4 years), baseline symptom score (20.2) and peak urinary flow (9.5 ml. per second) did not differ by treatment group. Transurethral resection of the prostate provided slightly greater improvement in urinary symptoms and flow. The pooled mean percentage improvement for urinary symptoms ranged from 59% to 68% with lasers and 63% to 77% with transurethral resection. Improvement for peak urinary flow ranged from 56% to 119% with lasers and 96% to 127% with transurethral resection of the prostate. Laser procedures resulted in fewer transfusions (less than 1% versus 7%) and strictures (0% to 7% versus 8%), and required shorter hospitalizations. Reoperation occurred more often (RR = 5.7) following laser procedures.
CONCLUSIONS: Laser techniques are a useful alternative to transurethral resection of the prostate for treating benign prostatic obstruction. Small sample sizes and differences in study design limit any definitive conclusions regarding the preferred type of laser technique.

Entities:  

Mesh:

Year:  2003        PMID: 12478138     DOI: 10.1097/01.ju.0000039605.47283.71

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

Review 1.  The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data.

Authors:  Jaspreet S Sandhu; Alexis E Te
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

2.  Recent advances in the surgical treatment of benign prostatic hyperplasia.

Authors:  Bernardo Rocco; Giancarlo Albo; Rafael Coelho Ferreira; Matteo Spinelli; Gabriele Cozzi; Paolo Dell'orto; Vipul Patel; Francesco Rocco
Journal:  Ther Adv Urol       Date:  2011-12

Review 3.  Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.

Authors:  Jaspreet S Sandhu; E Darracott Vaughan
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Safety and efficacy of the potassium-titanyl-phosphate laser and photoselective vaporization of the prostate for benign prostatic hyperplasia.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2006

5.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

Review 6.  A Review of Laser Treatment for Symptomatic BPH (Benign Prostatic Hyperplasia).

Authors:  Shiva Madhwan Nair; Marie Adrianne Pimentel; Peter John Gilling
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

Review 7.  Complications of laser prostatectomy: a review of recent data.

Authors:  Malte Rieken; Nicole Ebinger Mundorff; Gernot Bonkat; Stephen Wyler; Alexander Bachmann
Journal:  World J Urol       Date:  2010-01-06       Impact factor: 4.226

8.  [Thulium:YAG vaporesection of the prostate. First results].

Authors:  T Bach; T R W Herrmann; R Ganzer; A Blana; M Burchardt; A J Gross
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

9.  BPH procedural treatment: the case for value-based pay for performance.

Authors:  Mark Stovsky; Irina Jaeger
Journal:  Adv Urol       Date:  2008-12-21

10.  Therapeutic options in the treatment of benign prostatic hyperplasia.

Authors:  Jaspreet S Sandhu
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.